Global Payments Inc vs ResMed Inc. — how do they compare? Global Payments Inc trades at $79.29 (market cap $21.40B), while ResMed Inc. trades at $203.15 (market cap $28.80B). The key difference: ResMed Inc. is the larger of the two by market cap, and Global Payments Inc pays the higher dividend (1.28%). Which is the better fit depends on your goals.
| GPN | RMD | |
|---|---|---|
Market Cap | $21.40B | $28.80B |
Sector | Industrials | Health |
52-Week High | $90.01 | $293.73 |
52-Week Low | $62.47 | $182.82 |
Enterprise Value | $39.11B | $27.99B |
Dividend Yield | 1.28% | 1.21% |
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $75.89, down 1.25% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company maintains solid cash flow generation ($2.66B operating cash flow in 2025) and recently announced a $0.25 dividend. Despite negative net income margin and ROE, revenue trends show recovery potential with 2026 projections at $8.9B. Analyst consensus remains positive with 58% buy ratings and $81.56 price target.
GPN presents a mixed outlook with strong operational execution offset by profitability challenges. The Worldpay integration and AI-powered POS expansion offer growth catalysts, but margin pressure and rising debt levels pose risks. Current valuation at 28.76 P/E appears reasonable given the company's market position in payment technology, though investors should monitor competitive pressures in the fintech space.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Trailing returns across standard periods
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →